Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 16;7(1):101219.
doi: 10.1016/j.jhepr.2024.101219. eCollection 2025 Jan.

Application of a deep learning algorithm for the diagnosis of HCC

Affiliations

Application of a deep learning algorithm for the diagnosis of HCC

Philip Leung Ho Yu et al. JHEP Rep. .

Abstract

Background & aims: Hepatocellular carcinoma (HCC) is characterized by a high mortality rate. The Liver Imaging Reporting and Data System (LI-RADS) results in a considerable number of indeterminate observations, rendering an accurate diagnosis difficult.

Methods: We developed four deep learning models for diagnosing HCC on computed tomography (CT) via a training-validation-testing approach. Thin-slice triphasic CT liver images and relevant clinical information were collected and processed for deep learning. HCC was diagnosed and verified via a 12-month clinical composite reference standard. CT observations among at-risk patients were annotated using LI-RADS. Diagnostic performance was assessed by internal validation and independent external testing. We conducted sensitivity analyses of different subgroups, deep learning explainability evaluation, and misclassification analysis.

Results: From 2,832 patients and 4,305 CT observations, the best-performing model was Spatio-Temporal 3D Convolution Network (ST3DCN), achieving area under receiver-operating-characteristic curves (AUCs) of 0.919 (95% CI, 0.903-0.935) and 0.901 (95% CI, 0.879-0.924) at the observation (n = 1,077) and patient (n = 685) levels, respectively during internal validation, compared with 0.839 (95% CI, 0.814-0.864) and 0.822 (95% CI, 0.790-0.853), respectively for standard of care radiological interpretation. The negative predictive values of ST3DCN were 0.966 (95% CI, 0.954-0.979) and 0.951 (95% CI, 0.931-0.971), respectively. The observation-level AUCs among at-risk patients, 2-5-cm observations, and singular portovenous phase analysis of ST3DCN were 0.899 (95% CI, 0.874-0.924), 0.872 (95% CI, 0.838-0.909) and 0.912 (95% CI, 0.895-0.929), respectively. In external testing (551/717 patients/observations), the AUC of ST3DCN was 0.901 (95% CI, 0.877-0.924), which was non-inferior to radiological interpretation (AUC 0.900; 95% CI, 0.877--923).

Conclusions: ST3DCN achieved strong, robust performance for accurate HCC diagnosis on CT. Thus, deep learning can expedite and improve the process of diagnosing HCC.

Impact and implications: The clinical applicability of deep learning in HCC diagnosis is potentially huge, especially considering the expected increase in the incidence and mortality of HCC worldwide. Early diagnosis through deep learning can lead to earlier definitive management, particularly for at-risk patients. The model can be broadly deployed for patients undergoing a triphasic contrast CT scan of the liver to reduce the currently high mortality rate of HCC.

Keywords: AI; CT; HCC; Imaging; LIRADS; Liver cancer.

PubMed Disclaimer

Conflict of interest statement

W-KS received speaker’s fees from AstraZeneca, is an advisory board member and received speaker’s fees from Abbott, received research funding from Pfizer, Alexion Pharmaceuticals, Ribo Life Sciences and Boehringer Ingelheim, and is an advisory board member, received speaker’s fees and researching funding from Gilead Sciences. M-FY is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, and Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation, and Sysmex Corporation. The remaining authors have no conflict of interests. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Overall framework of the developed deep learning model, Spatio-Temporal 3D Convolution Network (ST3DCN), for predicting hepatocellular carcinoma (HCC)/non-HCC. (A) Complete architecture of ST3DCN. (B) Details of the efficient channel attention (ECA) and spatial attention (SA) blocks. P3D, pseudo 3D.
Fig. 2
Fig. 2
Patient selection process. 1Relevant clinical data were also collected. 2Post-treatment scans after percutaneous, transcatheter, or radiation therapy are assessed differently via LIRADS and were excluded. 3Two scans had prior intra-abdominal vascular coils inserted, hindering image quality. CT, computed tomography; LI-RADS, Liver Imaging Reporting and Data System.
Fig. 3
Fig. 3
AUC curves of different 3D deep learning models. (A) Internal validation for overall patients; (B) internal validation for at-risk patients; (C) external testing for overall patients; (D) external testing for at-risk patients. Among all models, Spatio-Temporal 3D Convolution Network (ST3DCN; blue line) had the highest diagnostic performance, achieving AUCs of 0.862 and 0.919 at the observation and patient level, respectively during internal validation and 0.881 and 0.901, respectively during external testing. (E) When discounting cholangiocarcinomas and liver metastases for overall patients in external testing, AUCs of 0.981 and 0.982, respectively were achieved. 3DResNet, Three-Dimensional Residual Network; 3DSE, Three-Dimensional Squeeze-and-Excitation; C3D, Convolutional Three-Dimensional.
Fig. 4
Fig. 4
Visualization of deep learning classification results. Heatmap plots for three different slices from the same computed tomography (CT) scan of three patients (A) with hepatocellular carcinoma (HCC) and (B) non-HCC. The odd rows depict the CT scan in the portovenous phase. For heatmaps in the even rows, the red color indicates the most risky area for HCC, while the blue area indicates the least risky area. Grad-CAM, gradient-weighted Class Activation Mapping.

References

    1. McGlynn K.A., Petrick J.L., El-Serag H.B. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. - PMC - PubMed
    1. Ferlay J., Erivik M., Lam F., et al. International Agency for Research on Cancer; Lyon, France: 2022. Global cancer observatory: cancer today.https://gco.iarc.fr/today
    1. McGlynn K.A., Petrick J.L., London W.T. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19:223–238. - PMC - PubMed
    1. Wang J.H., Wang C.C., Hung C.H., et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56:412–418. - PubMed
    1. Shindoh J., Andreou A., Aloia T.A., et al. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2013;20:1223–1229. - PMC - PubMed

LinkOut - more resources